Legal DNA Agreement

LEGAL DNA AGREEMENT

This Legal DNA Agreement (the Agreement) is entered into as of Effective Date: by and between Provider Name: , a with principal place of business at (hereinafter, the "Provider"), and Participant Name: , residing at (hereinafter, the "Participant").

RECITALS

WHEREAS, Provider operates a laboratory and/or genetic testing facility that collects, analyzes, stores and reports deoxyribonucleic acid (DNA) samples and derivative genetic data;

WHEREAS, Participant desires to provide a biological sample to Provider for the purpose of genetic testing, analysis and reporting under the terms and conditions set forth in this Agreement; and

WHEREAS, the parties wish to define the respective rights, obligations, confidentiality requirements, consent and limitations of use of the Sample and any Derived Data.

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the sufficiency of which is acknowledged, the parties agree as follows:

1. DEFINITIONS

1.1 "Sample" means any biological specimen provided by Participant to Provider for testing, including but not limited to saliva, buccal swab, blood or tissue.
1.2 "Derived Data" means all genetic, genomic, or other analytical data, reports, interpretations, files, summaries and metadata generated by Provider from the Sample, whether in human‑readable or machine‑readable form.
1.3 "Confidential Information" means non‑public information disclosed by either party that, by its nature or the circumstances of disclosure, ought reasonably to be treated as confidential, including Derived Data and personal information relating to the Participant.

2. CONSENT AND AUTHORIZATION

2.1 Participant hereby knowingly and voluntarily consents to the collection, testing and analysis of the Sample and authorizes Provider to generate, store and use Derived Data for the purposes set forth in this Agreement. Participant acknowledges receipt of a clear explanation of the nature and purpose of the testing, potential risks and limitations, and alternatives to testing.

2.2 Participant elects the following additional permissions (select applicable):
Consent to anonymized use of Derived Data for aggregated research and method development
Consent to sharing anonymized Derived Data with approved third‑party collaborators

3. COLLECTION, TESTING AND PROCEDURES

3.1 Provider will collect the Sample in accordance with accepted clinical or laboratory procedures and applicable law, and will perform testing using validated methods appropriate to the services requested by Participant or as described in an attached service order. Participant represents that all information provided in connection with collection is true and complete.

3.2 Sample Identification: Sample ID: ; Type of Sample: ; Collection Date:

4. OWNERSHIP; LICENSES

4.1 Participant retains ownership of the physical Sample; Provider retains ownership of laboratory records and Derived Data, subject to the license and confidentiality obligations set forth herein. Participant grants Provider a non‑exclusive, royalty‑free, worldwide license to use, reproduce and analyze the Sample and Derived Data solely to perform the services contemplated by this Agreement and as otherwise authorized herein.

5. CONFIDENTIALITY AND DATA PROTECTION

5.1 Provider will maintain appropriate administrative, physical and technical safeguards to protect Confidential Information and Derived Data from unauthorized access, disclosure, alteration or destruction, consistent with industry standards and applicable law.

5.2 Provider may disclose Derived Data to third parties only (a) as authorized in writing by Participant, (b) to contractors and agents bound by written confidentiality obligations, or (c) as required by law, in which case Provider will provide Participant notice of such disclosure unless legally prohibited.

6. RETENTION, STORAGE AND DESTRUCTION

6.1 Provider will retain the Sample and Derived Data for the period specified by applicable law or as otherwise agreed in writing. Unless Participant elects otherwise, Provider may retain anonymized aliquots and Derived Data for quality control and limited research purposes in accordance with Section 2.2.

6.2 At Participant's written request, Provider will, within a commercially reasonable time and subject to legal and regulatory obligations, destroy or return the Sample and, where feasible, delete non‑archival copies of Derived Data. Destruction will be documented in Provider's records.

7. REPORTING AND DISCLOSURE OF RESULTS

7.1 Provider will deliver test results to Participant in the manner specified by Participant or as set forth in the applicable service order. Provider makes no guarantee as to the interpretation of genetic findings beyond the content of the report.

7.2 If Provider identifies a result with immediate clinical significance, Provider may, consistent with applicable law and clinical policies, take reasonable steps to attempt to notify Participant or Participant's authorized clinician.

8. FEES; PAYMENT

8.1 Participant will pay fees for collection, testing, analysis and storage as set forth in the applicable invoice or service order. Payment is due in accordance with the payment terms agreed by the parties.

9. REPRESENTATIONS AND WARRANTIES

9.1 Participant represents and warrants that Participant is at least eighteen (18) years of age, has the legal capacity to consent to the collection and testing of the Sample, and that Participant's consent will not violate any contractual or legal obligations.

9.2 Provider represents and warrants that it will perform services in a professional manner consistent with industry standards and applicable laws and that it is accredited or licensed where required to perform the services described herein.

10. INDEMNIFICATION

10.1 Each party (the Indemnifying Party) will indemnify, defend and hold harmless the other party from and against any third‑party claims, losses, liabilities, damages and reasonable costs (including attorneys' fees) arising out of the Indemnifying Party's breach of this Agreement, gross negligence or willful misconduct.

11. LIMITATION OF LIABILITY

11.1 Except for liability arising from willful misconduct or indemnification obligations, neither party will be liable to the other for consequential, incidental, special or punitive damages, and each party's aggregate liability arising under or related to this Agreement will be limited to the total fees paid by Participant to Provider for the services that gave rise to the claim in the twelve (12) months preceding the claim.

12. TERM; TERMINATION

12.1 This Agreement commences on the Effective Date and continues until such time as all obligations have been fulfilled, unless earlier terminated by written agreement of the parties. Either party may terminate this Agreement for material breach by the other party if the breach remains uncured for thirty (30) days after written notice.

13. NOTICES

All notices required or permitted under this Agreement will be in writing and delivered to the addresses below by certified mail, overnight courier or electronic delivery with confirmation:

14. AMENDMENTS; WAIVER

14.1 This Agreement may be amended only by a written instrument signed by both parties. No waiver of any provision will be effective unless in writing signed by the waiving party. A waiver of any breach will not constitute a waiver of any other or subsequent breach.

15. GOVERNING LAW

15.1 This Agreement will be governed by and construed in accordance with the laws of the state or jurisdiction identified here: , without regard to conflict of laws principles.

16. ENTIRE AGREEMENT

16.1 This Agreement, together with any signed service orders or statements of work, constitutes the entire agreement between the parties with respect to its subject matter and supersedes all prior and contemporaneous agreements, proposals and representations, whether written or oral.

17. SEVERABILITY

17.1 If any provision of this Agreement is held invalid or unenforceable by a court of competent jurisdiction, the remaining provisions will remain in full force and effect and the parties will negotiate in good faith a valid provision that most nearly effects the parties' original intent.

18. COUNTERPARTS

18.1 This Agreement may be executed in counterparts, each of which will be deemed an original and all of which together will constitute one and the same instrument. Signatures transmitted by electronic image or PDF will be deemed original signatures for all purposes.

19. MISCELLANEOUS

19.1 Assignment. Neither party may assign this Agreement without the prior written consent of the other party, except that Provider may assign to an affiliate or in connection with a sale of substantially all of its assets. 19.2 Independent Contractors. The parties are independent contractors and nothing herein creates an employment, joint venture or partnership relationship.

ADDITIONAL INSTRUCTIONS / SPECIAL TERMS

Sign Now